Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer (NCT07720115) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer
United States30 participantsStarted 2027-01-07
Plain-language summary
To learn if the experimental drug S-531011 plus RadScopalTM radiation therapy can help to control previously treated metastatic colorectal cancer.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Prior treatment with an anti-CCR8 antibody.
. Tumor occupying \>80% of total liver volume, as assessed by the investigator and/or treating radiation oncologist.
. Prior XRT to the target lesion(s) selected for HD-XRT.
. Prior organ or tissue allograft.
. Presence or history of immunodeficiency that requires chronic use of systemic corticosteroids (≥ 10mg of prednisone equivalent per day) or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, corticosteroids or immunosuppressive drugs).
. Any anticancer therapy within the past 4 weeks before enrollment.
. Extended field radiation within the past 4 weeks or limited field radiation within the past 2 weeks before enrollment.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is still in Phase 2 and hasn't started recruiting yet — given that, how much do we actually know so far about whether S-531011 is safe, and how does that uncertainty compare to my other treatment options right now?
2The trial is specifically for people who have already been treated for metastatic colorectal cancer — based on my treatment history, would I even be a candidate worth discussing with the trial team when it does open?
3The primary thing this study is measuring is safety and side effects rather than whether the treatment shrinks tumors — does that mean the main goal is still figuring out if this combination is safe enough to use, and what would that mean for me as a participant?
4This trial combines a drug called S-531011 with something called RadScopal, which I understand involves radiation — can you explain how that combination works and what kinds of side effects I should realistically expect from both together?
5Since the trial isn't recruiting yet, how long might it be before it opens, and is it worth waiting for it or should we focus on other available treatments in the meantime?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
safety and adverse events (AEs)
Timeframe: Through study completion; an average of 1 year